AlphAIAlphAI — Financial news for AI agents
investing.comNOV 42 min read$ATS

ATS Corporation reports Q2 earnings miss, cuts guidance

ATS Corporation (TSX:ATS, NYSE:ATS) reported Q2 fiscal 2027 earnings below expectations, with adjusted EPS of $0.27 and revenue of $665.8 million, down 8.6% YoY. The company withdrew its full-year guidance, citing delays in non-life sciences businesses and tariff impacts. Q3 revenue is expected to be $640M-$680M. Order Bookings rose 12.7% YoY to $827M, led by life sciences.

Original reporting
investing.com
Published Nov 4, 2026, 11:19 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ATS
Bearish
medium confidence
Mentioned
$ATS
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ATSBearishHigh
01

Why it matters

The earnings miss and guidance cut suggest near‑term revenue pressure, but the company cites a robust order backlog and a cost‑saving program.

02

Market read

ATS's Q2 miss and guidance reduction are likely to trigger a short‑term sell‑off, with potential sector ripple effects.

03

What to watch

Tariff uncertainty may be temporary; order backlog remains strong.

Relevance 7/10Novelty 8/10Timing: after-hours reaction

Background

ATS is a provider of automation equipment for life‑sciences and non‑life‑sciences markets, listed on NYSE and TSX.

Company-level read

Ticker impact

$ATSBearishMedium confidence
Context

ATS reported Q2 earnings miss and cut its fiscal 2027 revenue guidance.

Expected impact

downward pressure as investors price in weaker earnings and guidance

Evidence & confidence

The miss and guidance cut are fresh, material information that typically leads to a sell‑off.

Market effects

Sector

The miss may weigh on the industrial automation and life‑sciences equipment sector.

Regional

Potentially modest impact on Canadian and U.S. markets where ATS trades.

Global

Limited; primarily a company‑specific event.

Counterpoint

What could challenge this read

If the restructuring program delivers cost savings, the stock could rebound on longer‑term upside.

Key entities

  • Executive
    Doug Wright

    CEO of ATS who commented on the results.

Read at source← All news

StoryATS Corp reports Q2 FY2027 earnings miss and withdraws full‑year guidance

Also covered by

1 outlet

Related articles

AUG 13
$ATSMedAI 8/10

ATS (ATS) Q1 2027 Earnings Call Transcript

ATS Corporation reported Q1 fiscal 2027 results on Aug. 6, 2026. Adjusted revenue was $698 million, down 5% y/y, and adjusted EPS was $0.35. Adjusted earnings from operations fell 13.4% to $68.1 million. Order backlog was $1.9 billion and Q2 revenue guidance was $660 million to $700 million. ATS also outlined an 18-month transformation program and $70m to $90m capex guidance.

fool.com6 min
AUG 7
$ATSMed

ATS Q1 Earnings Call Highlights

ATS said it will consolidate some European facilities and shift technical capabilities to sites with capacity. Management expects the first phase to deliver about CAD 20 million in annualized savings, about 30% of the total fixed-cost program (CAD 60-70 million). Q1 restructuring costs were CAD 5.7 million and non-cash charges CAD 21.5 million. ATS guided Q2 revenue to CAD 660-700 million.

yahoo.com6 min
AUG 6
$ATSMed

ATS Reports First Quarter Fiscal 2027 Results and Announces a Fixed Cost Transformation Program

ATS Corporation reported fiscal 2027 first-quarter results for the three months ended June 28, 2026. Revenues were C$693.7 million versus C$736.7 million a year earlier, with a C$0.3 million net loss. Adjusted EBITDA was C$92.9 million. ATS also announced an 18-month Fixed Cost Transformation Program, targeting 15% adjusted earnings from operations margin, with an initial European footprint consolidation and expected C$20 million annual cost reductions.

montrealgazette.com6 min
MAY 29
$ATSMedAI 9/10

ATS (ATS) Q4 2026 Earnings Call Transcript

ATS reported Q4 2026 adjusted revenues of $744 million (+3.2%); organic growth was 1.5% with a 1.7% FX benefit. Q4 adjusted earnings from operations rose 3.4% to $76.8 million; gross margin was 29.4%. Order bookings were $704 million (-18.4%) and backlog about $2 billion. Fiscal 2027 guidance calls for Q1 revenues $700–$740 million and modest full-year growth, with margin improving 50–75 bps.

fool.com6 min